Drugs / SHJ002
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04928144 | Jul → Sep 2021 | myopia | Sunhawk Vision Biotech, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06579287 | Jan 2025 → Dec 2026 expected | myopia | Sunhawk Vision Biotech, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06381986 | Jun 2024 → Apr 2025 | corneal disorder | Sunhawk Vision Biotech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05486728 | Feb → Dec 2023 | dry eye syndrome | Dreamhawk Vision Biotech, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHJ002 | “SHJ002 is an antisense for microRNA-328, and SHJ002 was formulated as ophthalmic solution for a novel microRNA therapy.” PMID 39244490 ↗ Sep 2024 |
| Action | Inhibit | “SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.” NCT05486728 ↗ |
| Modality | Antisense oligonucleotide | “SHJ002 is an antisense for microRNA-328” PMID 39244490 ↗ Sep 2024 |
| Route | Topical | “SHJ002 Ophthalmic Solution: topically administered to each eye BID for 84 days” NCT05486728 ↗ |